Biological Safety and Biocompatibility Evaluation for Japan Medical Device Registration

1. Key takeaways

Biological safety evaluation in Japan is not a standalone test report; it is an evidence chain that cross-references the Essential Principles, the risk management documentation, and the clinical evaluation. GRZAN recommends organizing the documentation as a closed loop — risk management identification → determination of evaluation items → testing and literature evidence → conclusions flowing back into risk management — rather than binding up ISO 10993 series reports and submitting them as they stand. The evaluation earns its place in the dossier only when each test, each conclusion, and each residual risk can be traced across these documents.

• The Essential Principles, established under Article 41, Paragraph 3 of the PMD Act, are the legal anchor for biological safety requirements.
• Evaluation items are determined by two inputs together: the contact site (surface contact, external communicating pathways, implantation, and so on) and the contact duration.
• Biological hazards identified in risk management must point to specific biological evaluation items; evaluation conclusions must flow back into the residual risk assessment.
• A one-way reference — doing only one direction of the cross-referencing — will be flagged and must be supplemented during review.
• The current notification numbers for biological safety evaluation are pending verification and must be confirmed on the MHLW website.

2. Legal basis

The biological safety evaluation sits at the intersection of the approval review criteria, the Essential Principles, and the QMS record requirements. The key sources are as follows.

• PMD Act Article 23-2-5, Paragraph 2: the judgment of quality, efficacy and safety in approval review.
• PMD Act Article 41, Paragraph 3: the Essential Principles for medical devices established by the Minister of Health, Labour and Welfare — applicable to both certification and approval.
• QMS Ordinance (MHLW Ordinance No. 169 of 2004, promulgated December 17, 2004): the standards for manufacturing control and quality control, including record management requirements related to biological evaluation.
• MHLW notifications concerning the biological safety evaluation of medical devices — the specific notification numbers and issue dates are pending verification and should be confirmed on the current pages of the MHLW website (see the verification checklist).
• Current statute: Act No. 145 of 1960.

3. Expert insights

Insight 1: The Essential Principles are the statutory landing point of biological evaluation.

Article 41, Paragraph 3 authorizes the Minister of Health, Labour and Welfare to establish the Essential Principles for medical devices, and biological safety falls within the safety requirements of that framework. When organizing documentation, companies should map each evaluation conclusion to the specific items of the Essential Principles, rather than simply stating compliance with ISO 10993. A declaration of ISO 10993 compliance describes a testing campaign; a mapping to the Essential Principles demonstrates legal conformity. The distinction matters in review, because the reviewer’s obligation is to judge conformity with the statutory requirements, and a dossier that performs that mapping for them shortens the path to a positive judgment. Where a requirement is satisfied by a combination of tests and literature, the mapping should show exactly which evidence carries which requirement.

Insight 2: Contact classification and contact duration are the two inputs that determine the evaluation items.

The evaluation items are determined jointly by the contact site — surface contact, external communicating pathways, implantation, and other categories — and the contact duration, such as short-term, long-term, or persistent contact. A common error among manufacturers is to apply a fixed table of evaluation items by product category while ignoring the specific contact conditions of the actual device. Two devices in the same category may warrant different evaluation scopes because they touch the body differently or for different durations. Building a contact condition determination table, and deriving the evaluation scope from it, turns the selection of tests into a justified decision rather than a habit, and it gives reviewers the rationale for why certain endpoints were evaluated and others were not.

Insight 3: Risk management and biological evaluation must cross-reference each other in both directions.

The biological hazards identified in the risk management file should point to the specific items of the biological evaluation; the conclusions of the biological evaluation should flow back into the residual risk assessment of risk management. A one-way reference — implementing only one of the two directions — will be raised during review and must be supplemented. The closed loop is what makes the evidence chain coherent: hazards drive tests, test results drive risk judgments, and unresolved risks drive further evaluation. Marking the corresponding sections in both documents makes the loop visible and verifiable, and it prevents the two documents from drifting apart as they are revised over time.

4. Practical recommendations

• Determine the evaluation items by contact site and contact duration. Build a contact condition determination table as the justification basis for the evaluation scope.
• Map the conclusions to the Essential Principles items. State clearly which piece of evidence satisfies each requirement.
• Establish two-way references between the risk management file and the evaluation report. Mark the corresponding sections in both documents.
• Verify the current notification numbers separately. The numbers and dates of the notifications on biological safety evaluation should be confirmed against the current MHLW pages.

5. Verification checklist

• □ Have the evaluation items been determined item by item according to contact site and contact duration?
• □ Have the conclusions been mapped to the specific items of the Essential Principles under Article 41, Paragraph 3 of the PMD Act?
• □ Have two-way references been established between the risk management file and the biological evaluation report?
• □ Have the numbers and dates of the current notifications on biological safety evaluation been confirmed on the MHLW website?
• □ Has the practice of replacing item-by-item argumentation with a general statement of ISO 10993 compliance been avoided?

Legal information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, in-country representative and local testing support for the Japanese market. Our team prepares J-GCP/J-QMS compliant dossiers, coordinates conformity assessments, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com